"Clinical trials are space travel": Factors of psychological response to recurrence among oncologists enrolling patients in treatment optimization trials.

"Clinical trials are space travel": Factors of psychological response to recurrence among oncologists enrolling patients in treatment optimization trials.
复制标题

DOI:
10.1002/cam4.6710
复制
发表时间:
2023-12
期刊:
影响因子:
4
通讯作者:
--
中科院分区:
医学3区
文献类型:
--
作者:

文献摘要

参考文献

相似文献

Cancer recurrence after treatment is a concern for patients and oncologists alike. The movement towards treatment optimization, with trials testing less than the current standard of care (SoC), complicates this experience. Our objective was to assess oncologists' psychological response to patient recurrence on optimization‐focused trials and identify factors that influence those experiences. Clinical oncologists participated in a semi‐structured interview regarding patient enrollment in treatment optimization trials. We identified factors that influence the degree of psychological response that the oncologist may feel after patient recurrence. Residual agreement analysis was used to identify whether differences in reported psychological response was associated with alternative emphases on identified factors. Thirty‐six oncologists identified 20 factors spanning five major themes that affected their psychological response to patient recurrence. All oncologists expressed willingness to enroll patients in treatment optimization clinical trials; however, half indicated that they were more likely to experience a negative psychological response after a treatment optimization trial than after a traditional intensification trial, and a quarter reported that patient recurrence on an optimization trial would impact their recommendations for future trial enrollment. Oncologists who reported more negative psychological responses to patient recurrence after participation in an optimization trial were more likely to emphasize introspective factors, while those who reported no difference in response emphasized patient‐ and process‐focused factors. Although most oncologists recognize the importance of treatment optimization trials, a significant proportion indicated a greater potential for psychological distress following patient recurrence in such trials and offered insight into how trial design and the process of patient enrollment can be improved to minimize those negative psychological responses.
DOI: 10.1186/s12885-022-09189-w
发表时间: 2022-02-04
期刊: BMC cancer
影响因子: 3.8
作者:
Andrews C;Childers TC;Wiseman KD;Lawhon V;Ingram S;Smith ML;Wolff AC;Wagner L;Rocque GB
通讯作者: Rocque GB
DOI: 10.1086/702470
发表时间: 2019-04-01
影响因子: 2.2
作者:
de Munck, Victor C.;Bennardo, Giovanni
通讯作者: Bennardo, Giovanni
DOI: 10.1163/15685373-12340160
发表时间: 2023-04-01
影响因子: 0.4
作者:
Dressler, William W.;Balieiro, Mauro C.;dos Santos, Jose Ernesto
通讯作者: dos Santos, Jose Ernesto
DOI: 10.1111/etho.12348
发表时间: 2022-06-29
期刊: ETHOS
影响因子: 0.6
作者:
Henderson, Nicole L.;Monocello, Lawrence T.;Dressler, William W.
通讯作者: Dressler, William W.
DOI: 10.1002/pon.4868
发表时间: 2018-12-01
期刊: PSYCHO-ONCOLOGY
影响因子: 3.6
作者:
Mehlis, Katja;Bierwirth, Elena;Winkler, Eva C.
通讯作者: Winkler, Eva C.